The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Summit Therapeutics presents updated Ivonescimab data from phase II studies at ESMO 2024 annual meeting: Miami Wednesday, September 18, 2024, 15:00 Hrs [IST] Summit Therapeutics I ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

The company recently announced for its Harmoni-2 phase 3 trial, conducted in China in partnership with Akeso, where its lung cancer drug Ivonescimab showed a better progression-free survival period ...